MEDPNC specializes in studying personalized treatments for cancer by analyzing the patient-specific protein network structures, and has developed a groundbreaking method that proposes the optimal drug combination for each individual patient and also predicts the efficacy of the treatment.
Tumors may be classified as similar for the purpose of diagnostics and treatment, despite them being biologically and molecularly different. This explains why the effectiveness of conventional treatment may not be equal among all patients.
Evaluation of the protein and biochemical processes in the body together with their relationship to the disease is crucial for deciding on the optimal treatment for the individual patient.
Targeting central proteins in personalized altered protein networks is essential for the purpose of restoring the required balanced state in the body tissue that will result in increased patient survival.
Who We Are?
Associate Professor Nataly Kravchenko-Balasha - CSO
An associate professor for Biophysics and Cancer Research at the Hebrew University of Jerusalem (HUJI). Has a B.Sc. with excellence in Biology and Mathematics as part of the Honors Program “AMIRIM” for outstanding students and a Ph.D. in Biochemistry at the HUJI. Comleted post doctoral studies in Biophysics and Physical Chemistry at Caltech, USA. Has received several prestigious awards, such as Info-Metrics Prize, USA, in 2015, and EMBO Fellowship, Europe in 2012, as well as several research grants including from the National Institutes of Health, NIH, USA.
Prof. Tamar Peretz - Medical Director
Former director of the Institute of Oncology at the Hadassah Hospital in Jerusalem and one of the leading breast cancer specialists in the world. Prof. Peretz’s genetic research and clinical studies have led to breakthrough discoveries on mutations in the BRCA1 gene that have led to new prevention, diagnosis and treatment strategies.
Prof. Raphael D. Levine - Advisory Board Member
Professor of Natural Philosophy at the Hebrew University of Jerusalem, a theorist and one of the pioneers and a leader of worldwide recognition, in the modern theory of chemically reactive collisions and unimolecular reactions. A recipient of numerous prizes, including the Wolf Prize in Chemistry and the EMET Prize in Exact Sciences.
Dr. Gil Pogozelich - Chairman
Highly experienced, for 20 years Gil has been leading successful technology startups. Now specializes in the development, integration and commercialization of Life Science technologies, with emphasis on the field of personalized medicine. Previously specialized in the management of complex development teams in algorithms and engineering, and has registered and co-registered a number of patents.